Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2016 (2016), Article ID 4517492, 14 pages
http://dx.doi.org/10.1155/2016/4517492
Review Article

From Normal Skin to Squamous Cell Carcinoma: A Quest for Novel Biomarkers

1Department of Dermatology and Allergology, Elias Emergency University Hospital, Bucharest, Romania
2Department of Biochemistry, Faculty of Dental Medicine, “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania
3Dermatology Research Laboratory, “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania
4Department of Oral and Maxillofacial Surgery, “Carol Davila” Central Military Emergency Hospital, Bucharest, Romania
5Department of Physiology, “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania
6Department of Medical Chemistry and Biochemistry, Faculty of Medicine, Medical University, Sofia, Bulgaria

Received 7 April 2016; Accepted 25 July 2016

Academic Editor: Simone Ribero

Copyright © 2016 Vlad Voiculescu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Alam and D. Ratner, “Cutaneous squamous-cell carcinoma,” The New England Journal of Medicine, vol. 344, no. 13, pp. 975–983, 2001. View at Publisher · View at Google Scholar · View at Scopus
  2. T. M. Johnson, D. E. Rowe, B. R. Nelson, and N. A. Swanson, “Squamous cell carcinoma of the skin (excluding lip and oral mucosa),” Journal of the American Academy of Dermatology, vol. 26, no. 3, pp. 467–484, 1992. View at Publisher · View at Google Scholar · View at Scopus
  3. D. E. Rowe, R. J. Carroll, and C. L. Day Jr., “Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip: implications for treatment modality selection,” Journal of the American Academy of Dermatology, vol. 26, no. 6, pp. 976–990, 1992. View at Publisher · View at Google Scholar · View at Scopus
  4. S. Ch'ng, A. Maitra, R. Lea, H. Brasch, and S. T. Tan, “Parotid metastasis—an independent prognostic factor for head and neck cutaneous squamous cell carcinoma,” Journal of Plastic, Reconstructive and Aesthetic Surgery, vol. 59, no. 12, pp. 1288–1293, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. A. S. Weinberg, C. A. Ogle, and E. K. Shim, “Metastatic cutaneous squamous cell carcinoma: an update,” Dermatologic Surgery, vol. 33, no. 8, pp. 885–899, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. T. Liu, Z. Lei, Z. Pan et al., “Genetic association between p53 codon 72 polymorphism and risk of cutaneous squamous cell carcinoma,” Tumor Biology, vol. 35, no. 4, pp. 3899–3903, 2014. View at Publisher · View at Google Scholar · View at Scopus
  7. E. De Vries, L. V. Van De Poll-Franse, W. J. Louwman, F. R. De Gruijl, and J. W. W. Coebergh, “Predictions of skin cancer incidence in the Netherlands up to 2015,” British Journal of Dermatology, vol. 152, no. 3, pp. 481–488, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. B. K. Armstrong and A. Kricker, “The epidemiology of UV induced skin cancer,” Journal of Photochemistry and Photobiology B: Biology, vol. 63, no. 1–3, pp. 8–18, 2001. View at Publisher · View at Google Scholar · View at Scopus
  9. T. L. Diepgen and V. Mahler, “Photoprotective properties of skin melanin,” British Journal of Dermatology, Supplement, vol. 146, no. 61, pp. 7–10, 2002. View at Google Scholar · View at Scopus
  10. V. Madan, J. T. Lear, and R.-M. Szeimies, “Non-melanoma skin cancer,” The Lancet, vol. 375, no. 9715, pp. 673–685, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. H. W. Rogers, M. A. Weinstock, A. R. Harris et al., “Incidence estimate of nonmelanoma skin cancer in the United States, 2006,” Archives of Dermatology, vol. 146, no. 3, pp. 283–287, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. R. G. Glogau, “The risk of progression to invasive disease,” Journal of the American Academy of Dermatology, vol. 42, no. 1, pp. S23–S24, 2000. View at Publisher · View at Google Scholar · View at Scopus
  13. K. Thestrup-Pedersen, L. Ravnborg, and F. Reymann, “Morbus Bowen. A description of the disease in 617 patients,” Acta Dermato-Venereologica, vol. 68, no. 3, pp. 236–239, 1988. View at Google Scholar · View at Scopus
  14. O. Warszawik-Hendzel, M. Olszewska, M. Maj, A. Rakowska, J. Czuwara, and L. Rudnicka, “Non-invasive diagnostic techniques in the diagnosis of squamous cell carcinoma,” Journal of Dermatological Case Reports, vol. 9, no. 4, pp. 89–97, 2015. View at Publisher · View at Google Scholar · View at Scopus
  15. M. A. Ghita, C. Caruntu, A. E. Rosca et al., “Reflectance confocal microscopy and dermoscopy for in vivo, non-invasive skin imaging of superficial basal cell carcinoma,” Oncology Letters, vol. 11, no. 5, pp. 3019–3024, 2016. View at Publisher · View at Google Scholar
  16. A. Kivisaari and V.-M. Kähäri, “Squamous cell carcinoma of the skin: emerging need for novel biomarkers,” World Journal of Clinical Oncology, vol. 4, no. 4, pp. 85–90, 2013. View at Publisher · View at Google Scholar
  17. C. M. Lohmann and A. R. Solomon, “Clinicopathologic variants of cutaneous squamous cell carcinoma,” Advances in Anatomic Pathology, vol. 8, no. 1, pp. 27–36, 2001. View at Publisher · View at Google Scholar · View at Scopus
  18. J. He, J. Wu, Y. Jiao et al., “IgH gene rearrangements as plasma biomarkers in non-Hodgkin's Lymphoma patients,” Oncotarget, vol. 2, no. 3, pp. 178–185, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. B. Faltas, “Circulating tumor cells in the cerebrospinal fluid: ‘tapping’ into diagnostic and predictive potential,” Oncotarget, vol. 2, no. 11, pp. 822–822, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. A. S. Patel, J. E. Allen, D. T. Dicker et al., “Identification and enumeration of circulating tumor cells in the cerebrospinal fluid of breast cancer patients with central nervous system metastases,” Oncotarget, vol. 2, no. 10, pp. 752–760, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. J. M. Silva, J. Silva, A. Sanchez et al., “Tumor DNA in plasma at diagnosis of breast cancer patients is a valuable predictor of disease-free survival,” Clinical Cancer Research, vol. 8, no. 12, pp. 3761–3766, 2002. View at Google Scholar · View at Scopus
  22. K. Koyanagi, T. Mori, S. J. O'Day, S. R. Martinez, H.-J. Wang, and D. S. B. Hoon, “Association of circulating tumor cells with serum tumor-related methylated DNA in peripheral blood of melanoma patients,” Cancer Research, vol. 66, no. 12, pp. 6111–6117, 2006. View at Publisher · View at Google Scholar · View at Scopus
  23. I. Van Der Auwera, D. Peeters, I. H. Benoy et al., “Circulating tumour cell detection: A direct comparison between the CellSearch System, the AdnaTest and CK-19/mammaglobin RT-PCR in patients with metastatic breast cancer,” British Journal of Cancer, vol. 102, no. 2, pp. 276–284, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. P.-Y. Lin and P.-C. Yang, “Circulating miRNA signature for early diagnosis of lung cancer,” EMBO Molecular Medicine, vol. 3, no. 8, pp. 436–437, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. S. Zanivan, A. Meves, K. Behrendt et al., “In vivo SILAC-based proteomics reveals phosphoproteome changes during mouse skin carcinogenesis,” Cell Reports, vol. 3, no. 2, pp. 552–566, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. C. Caruntu, D. Boda, G. Dumitrascu, C. Constantin, and M. Neagu, “Proteomics focusing on immune markers in psoriatic arthritis,” Biomarkers in Medicine, vol. 9, no. 6, pp. 513–528, 2015. View at Publisher · View at Google Scholar · View at Scopus
  27. T. Janvilisri, K. Leelawat, S. Roytrakul, A. Paemanee, and R. Tohtong, “Novel serum biomarkers to differentiate cholangiocarcinoma from benign biliary tract diseases using a proteomic approach,” Disease Markers, vol. 2015, Article ID 105358, 11 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus
  28. R. M. Sallam, “Proteomics in cancer biomarkers discovery: challenges and applications,” Disease Markers, vol. 2015, Article ID 321370, 12 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus
  29. A. Bulman, M. Neagu, and C. Constantin, “Immunomics in skin cancer—improvement in diagnosis, prognosis and therapy monitoring,” Current Proteomics, vol. 10, no. 3, pp. 202–217, 2013. View at Publisher · View at Google Scholar · View at Scopus
  30. C. P. Tanase, M. Neagu, R. Albulescu, and M. E. Hinescu, “Advances in pancreatic cancer detection,” Advances in Clinical Chemistry, vol. 51, pp. 145–180, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. C. P. Tanase, R. Albulescu, and M. Neagu, “Application of 3D hydrogel microarrays in molecular diagnostics: advantages and limitations,” Expert Review of Molecular Diagnostics, vol. 11, no. 5, pp. 461–462, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. C. P. Tanase, M. Neagu, and R. Albulescu, “Key signaling molecules in pituitary tumors,” Expert Review of Molecular Diagnostics, vol. 9, no. 8, pp. 859–877, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. M. Neagu, C. Constantin, G. R. Dumitrascu et al., “Inflammation markers in cutaneous melanoma—edgy biomarkers for prognosis,” Discoveries, vol. 3, no. 1, article e38, 2015. View at Google Scholar
  34. B. Calenic, M. Greabu, C. Caruntu, C. Tanase, and M. Battino, “Oral keratinocyte stem/progenitor cells: specific markers, molecular signaling pathways and potential uses,” Periodontology 2000, vol. 69, no. 1, pp. 68–82, 2015. View at Publisher · View at Google Scholar · View at Scopus
  35. M. Neagu, C. Caruntu, C. Constantin et al., “Chemically induced skin carcinogenesis: updates in experimental models (review),” Oncology Reports, vol. 35, no. 5, pp. 2516–2528, 2016. View at Publisher · View at Google Scholar
  36. V. Paulitschke, C. Gerner, E. Hofstätter et al., “Proteome profiling of keratinocytes transforming to malignancy,” Electrophoresis, vol. 36, no. 4, pp. 564–576, 2015. View at Publisher · View at Google Scholar · View at Scopus
  37. R. Pastila, “Effects of ultraviolet radiation on skin cell proteome,” in Radiation Proteomics, pp. 121–127, Springer, 2013. View at Google Scholar
  38. H. K. Muller and G. M. Woods, “Ultraviolet radiation effects on the proteome of skin cells,” in Radiation Proteomics, pp. 111–119, Springer, Berlin, Germany, 2013. View at Google Scholar
  39. A. Ouhtit, H. Konrad Muller, A. Gorny, and H. N. Ananthaswamy, “UVB-induced experimental carcinogenesis: dysregulation of apoptosis and p53 signalling pathway,” Redox Report, vol. 5, no. 2-3, pp. 128–129, 2000. View at Publisher · View at Google Scholar · View at Scopus
  40. A. Ouhtit, H. K. Muller, D. W. Davis, S. E. Ullrich, D. McConkey, and H. N. Ananthaswamy, “Temporal events in skin injury and the early adaptive responses in ultraviolet-irradiated mouse skin,” The American Journal of Pathology, vol. 156, no. 1, pp. 201–207, 2000. View at Publisher · View at Google Scholar · View at Scopus
  41. C. López-Camarillo, E. A. Ocampo, M. L. Casamichana, C. Pérez-Plasencia, E. Álvarez-Sánchez, and L. A. Marchat, “Protein kinases and transcription factors activation in response to UV-radiation of skin: implications for carcinogenesis,” International Journal of Molecular Sciences, vol. 13, no. 1, pp. 142–172, 2012. View at Publisher · View at Google Scholar · View at Scopus
  42. L. Rittié and G. J. Fisher, “UV-light-induced signal cascades and skin aging,” Ageing Research Reviews, vol. 1, no. 4, pp. 705–720, 2002. View at Publisher · View at Google Scholar · View at Scopus
  43. V. Bertrand-Vallery, E. Boilan, N. Ninane et al., “Repeated exposures to UVB induce differentiation rather than senescence of human keratinocytes lacking p16INK-4A,” Biogerontology, vol. 11, no. 2, pp. 167–181, 2010. View at Publisher · View at Google Scholar · View at Scopus
  44. K. M. Hunt, R. K. Srivastava, C. A. Elmets, and M. Athar, “The mechanistic basis of arsenicosis: pathogenesis of skin cancer,” Cancer Letters, vol. 354, no. 2, pp. 211–219, 2014. View at Publisher · View at Google Scholar · View at Scopus
  45. U. K. Udensi, A. J. Tackett, S. Byrum et al., “Proteomics-based identification of differentially abundant proteins from human keratinocytes exposed to arsenic trioxide,” Journal of Proteomics & Bioinformatics, vol. 7, no. 7, pp. 166–178, 2014. View at Publisher · View at Google Scholar · View at Scopus
  46. Y.-J. Qi, Q.-Y. He, Y.-F. Ma et al., “Proteomic identification of malignant transformation-related proteins in esophageal squamous cell carcinoma,” Journal of Cellular Biochemistry, vol. 104, no. 5, pp. 1625–1635, 2008. View at Publisher · View at Google Scholar · View at Scopus
  47. B. Akgül, L. Ghali, D. Davies, H. Pfister, I. M. Leigh, and A. Storey, “HPV8 early genes modulate differentiation and cell cycle of primary human adult keratinocytes,” Experimental Dermatology, vol. 16, no. 7, pp. 590–599, 2007. View at Publisher · View at Google Scholar · View at Scopus
  48. Y.-J. Lan, H. Chen, J.-Q. Chen, Q.-H. Lei, M. Zheng, and Z.-R. Shao, “Immunolocalization of vimentin, keratin 17, Ki-67, involucrin, β-catenin and E-cadherin in cutaneous squamous cell carcinoma,” Pathology & Oncology Research, vol. 20, no. 2, pp. 263–266, 2014. View at Publisher · View at Google Scholar · View at Scopus
  49. J. Shen, E. L. Abel, P. K. Riggs et al., “Proteomic and pathway analyses reveal a network of inflammatory genes associated with differences in skin tumor promotion susceptibility in DBA/2 and C57BL/6 mice,” Carcinogenesis, vol. 33, no. 11, pp. 2208–2219, 2012. View at Publisher · View at Google Scholar · View at Scopus
  50. M. E. Hemler, “Tetraspanin functions and associated microdomains,” Nature Reviews Molecular Cell Biology, vol. 6, no. 10, pp. 801–811, 2005. View at Publisher · View at Google Scholar · View at Scopus
  51. Q. Li, X. H. Yang, F. Xu et al., “Tetraspanin CD151 plays a key role in skin squamous cell carcinoma,” Oncogene, vol. 32, no. 14, pp. 1772–1783, 2013. View at Publisher · View at Google Scholar · View at Scopus
  52. T. Hara, S. Matsumura, F. Hakuno, S.-I. Takahashi, and K. Chida, “PKCα suppresses 7,12-dimethylbenz[a]anthracene-induced skin tumor formation,” Anticancer Research, vol. 32, no. 8, pp. 3097–3101, 2012. View at Google Scholar · View at Scopus
  53. C. Matei, M. Tampa, C. Caruntu et al., “Protein microarray for complex apoptosis monitoring of dysplastic oral keratinocytes in experimental photodynamic therapy,” Biological research, vol. 47, p. 33, 2014. View at Publisher · View at Google Scholar · View at Scopus
  54. http://emedicine.medscape.com/article/1965430-treatment.
  55. S.-J. Chen, T. Nakahara, M. Takahara et al., “Activation of the mammalian target of rapamycin signalling pathway in epidermal tumours and its correlation with cyclin-dependent kinase 2,” British Journal of Dermatology, vol. 160, no. 2, pp. 442–445, 2009. View at Publisher · View at Google Scholar · View at Scopus
  56. N. J. Wang, Z. Sanborn, K. L. Arnett et al., “Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 43, pp. 17761–17766, 2011. View at Publisher · View at Google Scholar · View at Scopus
  57. S. Yano, K. Kondo, M. Yamaguchi et al., “Distribution and function of EGFR in human tissue and the effect of EGFR tyrosine kinase inhibition,” Anticancer Research, vol. 23, no. 5, pp. 3639–3650, 2003. View at Google Scholar · View at Scopus
  58. N. W. Choong and E. E. W. Cohen, “Epidermal growth factor receptor directed therapy in head and neck cancer,” Critical Reviews in Oncology/Hematology, vol. 57, no. 1, pp. 25–43, 2006. View at Publisher · View at Google Scholar · View at Scopus
  59. S. Ch'ng, I. Low, D. Ng et al., “Epidermal growth factor receptor: a novel biomarker for aggressive head and neck cutaneous squamous cell carcinoma,” Human Pathology, vol. 39, no. 3, pp. 344–349, 2008. View at Publisher · View at Google Scholar · View at Scopus
  60. P. M. Riihilä, L. M. Nissinen, R. Ala-Aho et al., “Complement factor H: a biomarker for progression of cutaneous squamous cell carcinoma,” Journal of Investigative Dermatology, vol. 134, no. 2, pp. 498–506, 2014. View at Publisher · View at Google Scholar · View at Scopus
  61. D. Ricklin, G. Hajishengallis, K. Yang, and J. D. Lambris, “Complement: a key system for immune surveillance and homeostasis,” Nature Immunology, vol. 11, no. 9, pp. 785–797, 2010. View at Publisher · View at Google Scholar · View at Scopus
  62. S. R. De Córdoba and E. G. De Jorge, “Translational mini-review series on complement factor H: genetics and disease associations of human complement factor H,” Clinical & Experimental Immunology, vol. 151, no. 1, pp. 1–13, 2008. View at Publisher · View at Google Scholar · View at Scopus
  63. G. A. Silverman, P. I. Bird, R. W. Carrell et al., “The serpins are an expanding superfamily of structurally similar but functionally diverse proteins. Evolution, mechanism of inhibition, novel functions, and a revised nomenclature,” The Journal of Biological Chemistry, vol. 276, no. 36, pp. 33293–33296, 2001. View at Publisher · View at Google Scholar · View at Scopus
  64. R. H. P. Law, Q. Zhang, S. McGowan et al., “An overview of the serpin superfamily,” Genome Biology, vol. 7, article 216, 2006. View at Publisher · View at Google Scholar · View at Scopus
  65. C. A. Midgley, S. White, R. Howitt et al., “APC expression in normal human tissues,” The Journal of Pathology, vol. 181, no. 4, pp. 426–433, 1997. View at Google Scholar · View at Scopus
  66. P. Madsen, H. H. Rasmussen, H. Leffers et al., “Molecular cloning, occurrence, and expression of a novel partially secreted protein ‘psoriasis’ that is highly up-regulated in psoriatic skin,” Journal of Investigative Dermatology, vol. 97, no. 4, pp. 701–712, 1991. View at Publisher · View at Google Scholar · View at Scopus
  67. M. W. Nasser, Z. Qamri, Y. S. Deol et al., “S100A7 enhances mammary tumorigenesis through upregulation of inflammatory pathways,” Cancer Research, vol. 72, no. 3, pp. 604–615, 2012. View at Publisher · View at Google Scholar · View at Scopus
  68. J. E. Celis, H. H. Rasmussen, H. Vorum et al., “Bladder squamous cell carcinomas express psoriasin and externalize it to the urine,” Journal of Urology, vol. 155, no. 6, pp. 2105–2112, 1996. View at Publisher · View at Google Scholar · View at Scopus
  69. N. Moubayed, M. Weichenthal, J. Harder, E. Wandel, M. Sticherling, and R. Gläser, “Psoriasin (S100A7) is significantly up-regulated in human epithelial skin tumours,” Journal of Cancer Research and Clinical Oncology, vol. 133, no. 4, pp. 253–261, 2007. View at Publisher · View at Google Scholar · View at Scopus
  70. S. C. Tripathi, A. Matta, J. Kaur et al., “Nuclear S100A7 is associated with poor prognosis in head and neck cancer,” PLoS ONE, vol. 5, no. 8, Article ID e11939, 2010. View at Publisher · View at Google Scholar · View at Scopus
  71. J.-D. Fine, L. B. Johnson, M. Weiner, K.-P. Li, and C. Suchindran, “Epidermolysis bullosa and the risk of life-threatening cancers: the National EB Registry experience, 1986–2006,” Journal of the American Academy of Dermatology, vol. 60, no. 2, pp. 203–211, 2009. View at Publisher · View at Google Scholar · View at Scopus
  72. M. Toriseva and V.-M. Kähäri, “Proteinases in cutaneous wound healing,” Cellular and Molecular Life Sciences, vol. 66, no. 2, pp. 203–224, 2009. View at Publisher · View at Google Scholar · View at Scopus
  73. A. K. Kivisaari, M. Kallajoki, T. Mirtti et al., “Transformation-specific matrix metalloproteinases (MMP)-7 and MMP-13 are expressed by tumour cells in epidermolysis bullosa-associated squamous cell carcinomas,” British Journal of Dermatology, vol. 158, no. 4, pp. 778–785, 2008. View at Publisher · View at Google Scholar · View at Scopus
  74. A. K. Kivisaari, M. Kallajoki, R. Ala-Aho et al., “Matrix metalloproteinase-7 activates heparin-binding epidermal growth factor-like growth factor in cutaneous squamous cell carcinoma,” British Journal of Dermatology, vol. 163, no. 4, pp. 726–735, 2010. View at Publisher · View at Google Scholar · View at Scopus
  75. Y. Yamashiro, K. Takei, M. Umikawa et al., “Ectopic coexpression of keratin 8 and 18 promotes invasion of transformed keratinocytes and is induced in patients with cutaneous squamous cell carcinoma,” Biochemical and Biophysical Research Communications, vol. 399, no. 3, pp. 365–372, 2010. View at Publisher · View at Google Scholar · View at Scopus
  76. C. Bock, C. Kuhn, N. Ditsch et al., “Strong correlation between N-cadherin and CD133 in breast cancer: role of both markers in metastatic events,” Journal of Cancer Research and Clinical Oncology, vol. 140, no. 11, pp. 1873–1881, 2014. View at Publisher · View at Google Scholar · View at Scopus
  77. S. Chen, X. Song, Z. Chen et al., “CD133 expression and the prognosis of colorectal cancer: a systematic review and meta-analysis,” PLoS ONE, vol. 8, no. 2, Article ID e56380, 2013. View at Publisher · View at Google Scholar · View at Scopus
  78. S. Bidlingmaier, X. Zhu, and B. Liu, “The utility and limitations of glycosylated human CD133 epitopes in defining cancer stem cells,” Journal of Molecular Medicine, vol. 86, no. 9, pp. 1025–1032, 2008. View at Publisher · View at Google Scholar · View at Scopus
  79. A. Fusi, S. Ochsenreither, A. Busse, A. Rietz, and U. Keilholz, “Expression of the stem cell marker nestin in peripheral blood of patients with melanoma,” British Journal of Dermatology, vol. 163, no. 1, pp. 107–114, 2010. View at Publisher · View at Google Scholar · View at Scopus
  80. A. H. Yin, S. Miraglia, E. D. Zanjani et al., “AC133, a novel marker for human hematopoietic stem and progenitor cells,” Blood, vol. 90, no. 12, pp. 5002–5012, 1997. View at Google Scholar · View at Scopus
  81. L. Wen, X.-Z. Chen, K. Yang et al., “Prognostic value of cancer stem cell marker CD133 expression in gastric cancer: a systematic review,” PLoS ONE, vol. 8, no. 3, Article ID e59154, 2013. View at Publisher · View at Google Scholar · View at Scopus
  82. H. Al-Shagahin, K. Alkotyfan, H.-H. Müller, A. M. Sesterhenn, and J. A. Werner, “Cyfra 21-1 as a serum tumor marker for follow-up of patients with laryngeal and hypopharyngeal squamous cell carcinoma,” Anticancer Research, vol. 29, no. 8, pp. 3421–3425, 2009. View at Google Scholar · View at Scopus
  83. A. Banal, K. Hacene, E. Berthelot-Ruff, E. Mahé, X. Fontana, and M. F. Pichon, “Comparison of Cyfra 21-1 and SCC assays in head and neck tumours,” Tumor Biology, vol. 22, no. 1, pp. 27–35, 2001. View at Publisher · View at Google Scholar · View at Scopus
  84. J. Boucek, T. Mrkvan, M. Chovanec et al., “Regulatory T cells and their prognostic value for patients with squamous cell carcinoma of the head and neck,” Journal of Cellular and Molecular Medicine, vol. 14, no. 1-2, pp. 426–433, 2010. View at Publisher · View at Google Scholar · View at Scopus
  85. I. Doweck, M. Barak, E. Greenberg et al., “Cyfra 21-1: A new potential tumor marker for squamous cell carcinoma of head and neck,” Archives of Otolaryngology—Head and Neck Surgery, vol. 121, no. 2, pp. 177–181, 1995. View at Publisher · View at Google Scholar · View at Scopus
  86. C. Kuropkat, B. M. Lippert, and J. A. Werner, “Follow-up with serum Cyfra 21-1 in patients with squamous cell carcinomas of the head and neck,” Oncology, vol. 63, no. 3, pp. 280–285, 2002. View at Publisher · View at Google Scholar · View at Scopus
  87. C. Kuropkat and J. A. Werner, “Analytical and clinical evaluation of cyfra 21-1 by electrochemiluminescent immunoassay in head and neck squamous cell carcinoma,” The Journal of Laryngology & Otology, vol. 117, pp. 1007–1008, 2003. View at Google Scholar
  88. L.-P. Zhong, H.-G. Zhu, C.-P. Zhang, W.-T. Chen, and Z.-Y. Zhang, “Detection of serum Cyfra 21-1 in patients with primary oral squamous cell carcinoma,” International Journal of Oral and Maxillofacial Surgery, vol. 36, no. 3, pp. 230–234, 2007. View at Publisher · View at Google Scholar · View at Scopus
  89. K. Hamana, K. Uzawa, K. Ogawara et al., “Monitoring of circulating tumour-associated DNA as a prognostic tool for oral squamous cell carcinoma,” British Journal of Cancer, vol. 92, no. 12, pp. 2181–2184, 2005. View at Publisher · View at Google Scholar · View at Scopus
  90. S. Dasgupta, R. Koch, W. H. Westra et al., “Mitochondrial DNA mutation in normal margins and tumors of recurrent head and neck squamous cell carcinoma patients,” Cancer Prevention Research, vol. 3, no. 9, pp. 1205–1211, 2010. View at Publisher · View at Google Scholar · View at Scopus
  91. J. Nylandsted, K. Brand, and M. Jäättelä, “Heat shock protein 70 is required for the survival of cancer cells,” Annals of the New York Academy of Sciences, vol. 926, pp. 122–125, 2000. View at Google Scholar · View at Scopus
  92. T. Niwa, H. Saito, S. Imajoh-ohmi et al., “BRCA2 interacts with the cytoskeletal linker protein plectin to form a complex controlling centrosome localization,” Cancer Science, vol. 100, no. 11, pp. 2115–2125, 2009. View at Publisher · View at Google Scholar · View at Scopus
  93. Q. Wu, Y. Jiang, S. Cui, Y. Wang, and X. Wu, “The role of cofilin-l in vulvar squamous cell carcinoma: a marker of carcinogenesis, progression and targeted therapy,” Oncology Reports, vol. 35, pp. 2743–2754, 2016. View at Google Scholar
  94. Y. Jiang, R. Tian, S. Yu et al., “Clinical significance of galectin-7 in vulvar squamous cell carcinoma,” Oncology Letters, vol. 10, no. 6, pp. 3826–3831, 2015. View at Publisher · View at Google Scholar · View at Scopus
  95. G. I. Magnussen, E. Hellesylt, J. M. Nesland, C. G. Trope, V. A. Flørenes, and R. Holm, “High expression of wee1 is associated with malignancy in vulvar squamous cell carcinoma patients,” BMC Cancer, vol. 13, article 288, 2013. View at Publisher · View at Google Scholar · View at Scopus
  96. S. H. Nam-Cha, R. Serrano-Vargas, E. Escario et al., “CD133 expression in normal skin and in epithelial cutaneous tumors,” BioMed Research International, vol. 2013, Article ID 385604, 8 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  97. P. F. Zipfel and C. Skerka, “Complement regulators and inhibitory proteins,” Nature Reviews Immunology, vol. 9, no. 10, pp. 729–740, 2009. View at Publisher · View at Google Scholar · View at Scopus
  98. M. Schulze, C. J. Pruchno, M. Burns, P. J. Baker, R. J. Johnson, and W. G. Couser, “Glomerular C3c localization indicates ongoing immune deposit formation and complement activation in experimental glomerulonephritis,” American Journal of Pathology, vol. 142, no. 1, pp. 179–187, 1993. View at Google Scholar · View at Scopus
  99. P. F. Zipfel and C. Skerka, “FHL-1/reconectin: a human complement and immune regulator with cell-adhesive function,” Immunology Today, vol. 20, no. 3, pp. 135–140, 1999. View at Publisher · View at Google Scholar · View at Scopus
  100. M. Schulze, C. J. Pruchno, M. Burns, P. J. Baker, R. J. Johnson, and W. G. Couser, “Glomerular C3c localization indicates ongoing immune deposit formation and complement activation in experimental glomerulonephritis,” The American Journal of Pathology, vol. 142, no. 1, pp. 179–187, 1993. View at Google Scholar · View at Scopus
  101. A. Laine, A. Leroy, E. Hachulla, M. Davril, and J.-P. Dessaint, “Comparison of the effects of purified human α1-antichymotrypsin and α1-proteinase inhibitor on NK cytotoxicity: only α1-proteinase inhibitor inhibits natural killing,” Clinica Chimica Acta, vol. 190, no. 3, pp. 163–173, 1990. View at Publisher · View at Google Scholar · View at Scopus
  102. I. Zelvyte, T. Stevens, U. Westin, and S. Janciauskiene, “αl-antitrypsin and its C-terminal fragment attenuate effects of degranulated neutrophil-conditioned medium on lung cancer HCC cells, in vitro,” Cancer Cell International, vol. 4, article 7, 2004. View at Publisher · View at Google Scholar · View at Scopus
  103. L. F. Congote and N. Temmel, “The C-terminal 26-residue peptide of serpin A1 stimulates proliferation of breast and liver cancer cells: role of protein kinase C and CD47,” FEBS Letters, vol. 576, no. 3, pp. 343–347, 2004. View at Publisher · View at Google Scholar · View at Scopus
  104. K. J. Smith, K. A. Johnson, T. M. Bryan et al., “The APC gene product in normal and tumor cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 90, no. 7, pp. 2846–2850, 1993. View at Publisher · View at Google Scholar · View at Scopus
  105. S. M. Powell, N. Zilz, Y. Beazer-Barclay et al., “APC mutations occur early during colorectal tumorigenesis,” Nature, vol. 359, no. 6392, pp. 235–237, 1992. View at Publisher · View at Google Scholar · View at Scopus
  106. O. M. Sieber, I. P. Tomlinson, and H. Lamlum, “The adenomatous polyposis coli (APC) tumour suppressor—genetics, function and disease,” Molecular Medicine Today, vol. 6, no. 12, pp. 462–469, 2000. View at Google Scholar
  107. B. A. J. Ponder, “Molecular genetics of cancer,” British Medical Journal, vol. 304, no. 6836, pp. 1234–1236, 1992. View at Publisher · View at Google Scholar · View at Scopus
  108. H. Chai and R. E. Brown, “Field effect in cancer–an update,” Annals of Clinical & Laboratory Science, vol. 39, no. 4, pp. 331–337, 2009. View at Google Scholar · View at Scopus
  109. M. T. Bastiaens, J. A. C. Ter Huurne, C. Kielich et al., “Melanocortin-1 receptor gene variants determine the risk of nonmelanoma skin cancer independently of fair skin and red hair,” The American Journal of Human Genetics, vol. 68, no. 4, pp. 884–894, 2001. View at Publisher · View at Google Scholar · View at Scopus
  110. C. N. Parris, S. Jezzard, A. Silver, R. MacKie, J. M. McGregor, and R. F. Newbold, “Telomerase activity in melanoma and non-melanoma skin cancer,” British Journal of Cancer, vol. 79, no. 1, pp. 47–53, 1999. View at Publisher · View at Google Scholar · View at Scopus
  111. D. E. Brash, “Roles of the transcription factor p53 in keratinocyte carcinomas,” British Journal of Dermatology, vol. 154, pp. 8–10, 2006. View at Publisher · View at Google Scholar · View at Scopus
  112. C. L. Benjamin and H. N. Ananthaswamy, “p53 and the pathogenesis of skin cancer,” Toxicology and Applied Pharmacology, vol. 224, no. 3, pp. 241–248, 2007. View at Publisher · View at Google Scholar · View at Scopus
  113. M. Farshchian, A. Kivisaari, R. Ala-Aho et al., “Serpin peptidase inhibitor clade a member 1 (SerpinA1) is a novel biomarker for progression of cutaneous squamous cell carcinoma,” American Journal of Pathology, vol. 179, no. 3, pp. 1110–1119, 2011. View at Publisher · View at Google Scholar · View at Scopus
  114. Z. Qi, T. Li, F. Kong et al., “The characteristics and function of S100A7 induction in squamous cell carcinoma: heterogeneity, promotion of cell proliferation and suppression of differentiation,” PLoS ONE, vol. 10, no. 6, Article ID e0128887, 2015. View at Publisher · View at Google Scholar · View at Scopus
  115. M. R. Kesting, H. Sudhoff, R. J. Hasler et al., “Psoriasin (S100A7) up-regulation in oral squamous cell carcinoma and its relation to clinicopathologic features,” Oral Oncology, vol. 45, no. 8, pp. 731–736, 2009. View at Publisher · View at Google Scholar · View at Scopus
  116. C. Pourreyron, M. Chen, J. A. McGrath, J. C. Salas-Alanis, A. P. South, and I. M. Leigh, “High levels of type VII collagen expression in recessive dystrophic epidermolysis bullosa cutaneous squamous cell carcinoma keratinocytes increases PI3K and MAPK signalling, cell migration and invasion,” British Journal of Dermatology, vol. 170, no. 6, pp. 1256–1265, 2014. View at Publisher · View at Google Scholar · View at Scopus
  117. S. H. Yuspa, P. Hawley-Nelson, B. Koehler, and J. R. Stanley, “A survey of transformation markers in differentiating epidermal cell lines in culture,” Cancer Research, vol. 40, no. 12, pp. 4694–4703, 1980. View at Google Scholar · View at Scopus
  118. Z. Chen, C. W. Smith, D. Kiel, and C. Van Waes, “Metastastic variants derived following in vivo tumor progression of an in vitro transformed squamous cell carcinoma line acquire a differential growth advantage requiring tumor-host interaction,” Clinical & Experimental Metastasis, vol. 15, no. 5, pp. 527–537, 1997. View at Publisher · View at Google Scholar · View at Scopus
  119. R. Moll, M. Divo, and L. Langbein, “The human keratins: biology and pathology,” Histochemistry and Cell Biology, vol. 129, no. 6, pp. 705–733, 2008. View at Publisher · View at Google Scholar · View at Scopus
  120. U. Raul, S. Sawant, P. Dange, R. Kalraiya, A. Ingle, and M. Vaidya, “Implications of cytokeratin 8/18 filament formation in stratified epithelial cells: induction of transformed phenotype,” International Journal of Cancer, vol. 111, no. 5, pp. 662–668, 2004. View at Publisher · View at Google Scholar · View at Scopus
  121. H. Bühler and G. Schaller, “Transfection of keratin 18 gene in human breast cancer cells causes induction of adhesion proteins and dramatic regression of malignancy in vitro and in vivo,” Molecular Cancer Research, vol. 3, no. 7, pp. 365–371, 2005. View at Publisher · View at Google Scholar · View at Scopus
  122. E. B. Pasquale, “Eph receptors and ephrins in cancer: bidirectional signalling and beyond,” Nature Reviews Cancer, vol. 10, no. 3, pp. 165–180, 2010. View at Publisher · View at Google Scholar · View at Scopus
  123. D. B. Nikolov, K. Xu, and J. P. Himanen, “Eph/ephrin recognition and the role of Eph/ephrin clusters in signaling initiation,” Biochimica et Biophysica Acta—Proteins and Proteomics, vol. 1834, no. 10, pp. 2160–2165, 2013. View at Publisher · View at Google Scholar · View at Scopus
  124. H. Guo, H. Miao, L. Gerber et al., “Disruption of EphA2 receptor tyrosine kinase leads to increased susceptibility to carcinogenesis in mouse skin,” Cancer Research, vol. 66, no. 14, pp. 7050–7058, 2006. View at Publisher · View at Google Scholar · View at Scopus
  125. M. Farshchian, L. Nissinen, E. Siljamäki et al., “EphB2 promotes progression of cutaneous squamous cell carcinoma,” Journal of Investigative Dermatology, vol. 135, no. 7, pp. 1882–1892, 2015. View at Publisher · View at Google Scholar · View at Scopus
  126. Q. Wu, Z. Suo, B. Risberg, M. G. Karlsson, K. Villman, and J. M. Nesland, “Expression of Ephb2 and Ephb4 in breast carcinoma,” Pathology and Oncology Research, vol. 10, no. 1, pp. 26–33, 2004. View at Publisher · View at Google Scholar · View at Scopus
  127. K. Sellheyer, “Basal cell carcinoma: cell of origin, cancer stem cell hypothesis and stem cell markers,” British Journal of Dermatology, vol. 164, no. 4, pp. 696–711, 2011. View at Publisher · View at Google Scholar · View at Scopus
  128. K. Sellheyer, P. Nelson, and D. Krahl, “Dermatofibrosarcoma protuberans: a tumour of nestin-positive cutaneous mesenchymal stem cells?” British Journal of Dermatology, vol. 161, no. 6, pp. 1317–1322, 2009. View at Publisher · View at Google Scholar · View at Scopus
  129. I. González-Herrero, I. Romero-Camarero, J. Cañueto et al., “CD133+ cell content correlates with tumour growth in melanomas from skin with chronic sun-induced damage,” British Journal of Dermatology, vol. 169, no. 4, pp. 830–837, 2013. View at Publisher · View at Google Scholar · View at Scopus
  130. W. Ding, M. Mouzaki, H. You et al., “CD133+ liver cancer stem cells from methionine adenosyl transferase 1A–deficient mice demonstrate resistance to transforming growth factor (TGF)-β–induced apoptosis,” Hepatology, vol. 49, no. 4, pp. 1277–1286, 2009. View at Publisher · View at Google Scholar · View at Scopus
  131. L. Yu, L. Zhou, S. Wu et al., “Clinicopathological significance of cancer stem cells marked by CD133 and KAI1/CD82 expression in laryngeal squamous cell carcinoma,” World Journal of Surgical Oncology, vol. 12, no. 1, article 118, 2014. View at Publisher · View at Google Scholar · View at Scopus
  132. G. Alvarez, A. Perry, B. R. Tan, and H. L. Wang, “Expression of epidermal growth factor receptor in squamous cell carcinomas of the anal canal is independent of gene amplification,” Modern Pathology, vol. 19, no. 7, pp. 942–949, 2006. View at Publisher · View at Google Scholar · View at Scopus
  133. E. E. W. Cohen, F. Rosen, W. M. Stadler et al., “Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck,” Journal of Clinical Oncology, vol. 21, no. 10, pp. 1980–1987, 2003. View at Publisher · View at Google Scholar · View at Scopus
  134. D. Soulieres, N. N. Senzer, E. E. Vokes, M. Hidalgo, S. S. Agarvala, and L. L. Siu, “Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck,” Journal of Clinical Oncology, vol. 22, no. 1, pp. 77–85, 2004. View at Publisher · View at Google Scholar · View at Scopus
  135. J. Trigo, R. Hitt, P. Koralewski et al., “Cetuximab monotherapy is active in patients (pts) with platinum-refractory recurrent/metastatic squamous cell carcinoma of the head and neck (scchn): results of a phase II study,” in Proceedings of the ASCO Annual Meeting, p. 5502, 2004.
  136. B. Glisson, E. Kim, M. Kies et al., “Phase II study of gefitinib in patients with metastatic/recurrent squamous cell carcinoma of the skin,” in Proceedings of the ASCO Annual Meeting, p. 5531, 2006.
  137. A. M. Niemann, T. Goeroegh, S. Gottschlich, B. M. Lippert, and J. A. Werner, “Cut-off value determination of CYFRA 21-1 for squamous cell carcinomas of the head and neck (SCCHN),” Anticancer Research, vol. 17, no. 4, pp. 2859–2860, 1997. View at Google Scholar · View at Scopus
  138. T. Muley, T.-H. Fetz, H. Dienemann et al., “Tumor volume and tumor marker index based on CYFRA 21-1 and CEA are strong prognostic factors in operated early stage NSCLC,” Lung Cancer, vol. 60, no. 3, pp. 408–415, 2008. View at Publisher · View at Google Scholar · View at Scopus
  139. M. Tomita, T. Shimizu, T. Ayabe, A. Yonei, and T. Onitsuka, “Prognostic significance of tumour marker index based on preoperative CEA and CYFRA 21-1 in non-small cell lung cancer,” Anticancer Research, vol. 30, no. 7, pp. 3099–3102, 2010. View at Google Scholar · View at Scopus
  140. F. Balkwill and A. Mantovani, “Inflammation and cancer: back to virchow?” The Lancet, vol. 357, no. 9255, pp. 539–545, 2001. View at Publisher · View at Google Scholar · View at Scopus
  141. M. J. Gunter, R. Stolzenberg-Solomon, A. J. Cross et al., “A prospective study of serum C-reactive protein and colorectal cancer risk in men,” Cancer Research, vol. 66, no. 4, pp. 2483–2487, 2006. View at Publisher · View at Google Scholar · View at Scopus
  142. Y.-P. Hsu, C.-H. Hsieh, H.-T. Chien et al., “Serum markers of CYFRA 21-1 and C-reactive proteins in oral squamous cell carcinoma,” World Journal of Surgical Oncology, vol. 13, article 253, 2015. View at Publisher · View at Google Scholar · View at Scopus
  143. K. Uzawa, T. Baba, F. Uchida et al., “Circulating tumor-derived mutant mitochondrial DNA: a predictive biomarker of clinical prognosis in human squamous cell carcinoma,” Oncotarget, vol. 3, no. 7, pp. 670–677, 2012. View at Publisher · View at Google Scholar · View at Scopus
  144. R. Barrasso, J. De Brux, O. Croissant, and G. Orth, “High prevalence of papillomavirus-associated penile intraepithelial neoplasia in sexual partners of women with cervical intraepithelial neoplasia,” The New England Journal of Medicine, vol. 317, no. 15, pp. 916–923, 1987. View at Publisher · View at Google Scholar · View at Scopus
  145. A. G. Maiche, “Epidemiological aspects of cancer of the penis in Finland,” European Journal of Cancer Prevention, vol. 1, no. 2, pp. 153–158, 1992. View at Publisher · View at Google Scholar · View at Scopus
  146. C. Maden, K. J. Sherman, A. M. Beckmann et al., “History of circumcision, medical conditions, and sexual activity and risk of penile cancer,” Journal of the National Cancer Institute, vol. 85, no. 1, pp. 19–24, 1993. View at Publisher · View at Google Scholar · View at Scopus
  147. M. A. Scheiner, M. M. Campos, A. A. Ornellas, E. W. Chin, M. H. Ornellas, and M. J. Andrada-Serpa, “Human papillomavirus and penile cancers in Rio de Janeiro, Brazil: HPV typing and clinical features,” The International Brazilian Journal of Urology, vol. 34, no. 4, pp. 467–474, 2008. View at Publisher · View at Google Scholar · View at Scopus
  148. L. Koifman, A. J. Vides, N. Koifman, J. P. Carvalho, and A. A. Ornellas, “Epidemiological aspects of penile cancer in Rio de Janeiro: evaluation of 230 cases,” International Brazilian Journal of Urology, vol. 37, no. 2, pp. 231–240, 2011. View at Publisher · View at Google Scholar · View at Scopus
  149. M. S. Campo, S. V. Graham, M. S. Cortese et al., “HPV-16 E5 down-regulates expression of surface HLA class I and reduces recognition by CD8 T cells,” Virology, vol. 407, no. 1, pp. 137–142, 2010. View at Publisher · View at Google Scholar · View at Scopus
  150. L. Koifman, P. Ornellas, A. A. Ornellas et al., “Proteomics analysis of tissue samples from patients with squamous cell carcinoma of the penis and positive to human papillomavirus,” International Brazilian Journal of Urology, vol. 41, no. 4, pp. 642–654, 2015. View at Publisher · View at Google Scholar · View at Scopus
  151. M. Del Pino, L. Rodriguez-Carunchio, and J. Ordi, “Pathways of vulvar intraepithelial neoplasia and squamous cell carcinoma,” Histopathology, vol. 62, no. 1, pp. 161–175, 2013. View at Publisher · View at Google Scholar · View at Scopus
  152. M. Neagu, C. Constantin, and C. Tanase, “Immune-related biomarkers for diagnosis/prognosis and therapy monitoring of cutaneous melanoma,” Expert Review of Molecular Diagnostics, vol. 10, no. 7, pp. 897–919, 2010. View at Publisher · View at Google Scholar · View at Scopus
  153. M. Neagu, C. Constantin, C. Tanase, and D. Boda, “Patented biomarker panels in early detection of cancer,” Recent Patents on Biomarkers, vol. 1, pp. 10–24, 2011. View at Google Scholar
  154. M. Neagu, “The immune system—a hidden treasure for biomarker discovery in cutaneous melanoma,” Advances in Clinical Chemistry, vol. 58, pp. 89–140, 2012. View at Publisher · View at Google Scholar · View at Scopus
  155. M. Neagu, C. Constantin, and S. Zurac, “Immune parameters in the prognosis and therapy monitoring of cutaneous melanoma patients: experience, role, and limitations,” BioMed Research International, vol. 2013, Article ID 107940, 13 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  156. C. M. Hay, J. A. Lachance, F. Lucas, K. A. Smith, and M. A. Jones, “Biomarkers p16, human papillomavirus and p53 predict recurrence and survival in early stage squamous cell carcinoma of the vulva,” Journal of Lower Genital Tract Disease, vol. 20, no. 3, pp. 252–256, 2016. View at Google Scholar
  157. M. Lagerstedt, R. Huotari-Orava, R. Nyberg, J. U. Mäenpää, E. Snellman, and S.-L. Laasanen, “Reduction in ERRα is associated with lichen sclerosus and vulvar squamous cell carcinoma,” Gynecologic Oncology, vol. 139, no. 3, pp. 536–540, 2015. View at Publisher · View at Google Scholar · View at Scopus